InMed Pharmaceuticals INM Stock
InMed Pharmaceuticals Price Chart
InMed Pharmaceuticals INM Financial and Trading Overview
| InMed Pharmaceuticals stock price | 1.59 USD |
| Previous Close | 1.57 USD |
| Open | 1.55 USD |
| Bid | 1.14 USD x 200 |
| Ask | 1.95 USD x 200 |
| Day's Range | 1.49 - 1.63 USD |
| 52 Week Range | 0.58 - 5.5 USD |
| Volume | 194.53K USD |
| Avg. Volume | 1.69M USD |
| Market Cap | 5.17M USD |
| Beta (5Y Monthly) | 0.574 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
INM Valuation Measures
| Enterprise Value | 389.53K USD |
| Trailing P/E | N/A |
| Forward P/E | -0.2496 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.0459887 |
| Price/Book (mrq) | 0.45627376 |
| Enterprise Value/Revenue | 0.079 |
| Enterprise Value/EBITDA | -0.05 |
Trading Information
InMed Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.574 |
| 52-Week Change | -53.012% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 5.5 USD |
| 52 Week Low | 0.58 USD |
| 50-Day Moving Average | 0.87 USD |
| 200-Day Moving Average | 1.38 USD |
INM Share Statistics
| Avg. Volume (3 month) | 1.69M USD |
| Avg. Daily Volume (10-Days) | 10.04M USD |
| Shares Outstanding | 3.31M |
| Float | 1.97M |
| Short Ratio | 1.02 |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 21.86% |
| Shares Short | 26.6K |
| Short % of Float | 0.80% |
| Short % of Shares Outstanding | 0.80% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | June 30, 2026 |
Profitability
| Profit Margin | -172.17% |
| Operating Margin (ttm) | -162.75% |
| Gross Margin | 34.52% |
| EBITDA Margin | -158.50% |
Management Effectiveness
| Return on Assets (ttm) | -54.60% |
| Return on Equity (ttm) | -112.64% |
Income Statement
| Revenue (ttm) | 4.94M USD |
| Revenue Per Share (ttm) | 1.47 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 1.71M USD |
| EBITDA | -7834568 USD |
| Net Income Avi to Common (ttm) | -7836520 USD |
| Diluted EPS (ttm) | -1.47 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.2M USD |
| Total Cash Per Share (mrq) | 1.57 USD |
| Total Debt (mrq) | 420.15K USD |
| Total Debt/Equity (mrq) | 6.1 USD |
| Current Ratio (mrq) | 3.115 |
| Book Value Per Share (mrq) | 3.419 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7457501 USD |
| Levered Free Cash Flow (ttm) | -3935634 USD |
Profile of InMed Pharmaceuticals
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 885 West Georgia Street |
| ZIP | V6C 3E8 |
| Phone | 604 669 7207 |
| Website | https://www.inmedpharma.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Q&A For InMed Pharmaceuticals Stock
What is a current INM stock price?
InMed Pharmaceuticals INM stock price today per share is 1.59 USD.
How to purchase InMed Pharmaceuticals stock?
You can buy INM shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for InMed Pharmaceuticals?
The stock symbol or ticker of InMed Pharmaceuticals is INM.
Which industry does the InMed Pharmaceuticals company belong to?
The InMed Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.
How many shares does InMed Pharmaceuticals have in circulation?
The max supply of InMed Pharmaceuticals shares is 3.31M.
What is InMed Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
InMed Pharmaceuticals PE Ratio is now.
What was InMed Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
InMed Pharmaceuticals EPS is -1.47 USD over the trailing 12 months.
Which sector does the InMed Pharmaceuticals company belong to?
The InMed Pharmaceuticals sector is Healthcare.
InMed Pharmaceuticals INM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Australia Completion Cap NQAUCCN | 1088.27 AUD 720.28 USD |
0
|
— — | 1083.1 AUD 716.86 USD | 1088.97 AUD 720.74 USD | — - | — — |
- {{ link.label }} {{link}}